Technical Analysis for ARCT - Arcturus Therapeutics Ltd.

Grade Last Price % Change Price Change
F 50.59 -6.25% -3.37
ARCT closed down 6.25 percent on Wednesday, March 3, 2021, on 38 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ARCT trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Shooting Star Candlestick Bearish -6.25%
Doji - Bearish? Reversal -6.25%
Earnings Movers Other -6.25%
Wide Bands Range Expansion -6.25%
Oversold Stochastic Weakness -6.25%
Narrow Range Bar Range Contraction -7.41%
NR7 Range Contraction -7.41%
Earnings Movers Other -7.41%
Older End-of-Day Signals for ARCT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 14 hours ago
Down 5% about 19 hours ago
Down 3% about 19 hours ago
Down 2 % about 19 hours ago
Down 1% about 19 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Arcturus Therapeutics Ltd. Description

Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine. MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits. ADAIR is an oral, semi-solid, liquid-filled, hard gelatin capsule of an abuse-deterrent IR formulation of dextroamphetamine sulfate, which is manufactured as 10 mg capsules.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pharmaceutical Industry Drugs Health Sciences Pharmacology Dosage Forms Euphoriants Amphetamine Cognitive Disorders Glutamate Adhd Tablet Mdx Taar1 Agonists

Is ARCT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 129.71
52 Week Low 8.51
Average Volume 1,978,797
200-Day Moving Average 57.71
50-Day Moving Average 69.64
20-Day Moving Average 67.86
10-Day Moving Average 56.40
Average True Range 6.29
ADX 24.77
+DI 15.89
-DI 35.01
Chandelier Exit (Long, 3 ATRs ) 70.30
Chandelier Exit (Short, 3 ATRs ) 67.68
Upper Bollinger Band 93.80
Lower Bollinger Band 41.92
Percent B (%b) 0.17
BandWidth 76.46
MACD Line -5.89
MACD Signal Line -4.00
MACD Histogram -1.8871
Fundamentals Value
Market Cap 1.24 Billion
Num Shares 24.5 Million
EPS -1.26
Price-to-Earnings (P/E) Ratio -40.12
Price-to-Sales 140.45
Price-to-Book 7.63
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 59.31
Resistance 3 (R3) 60.14 58.06 57.85
Resistance 2 (R2) 58.06 55.84 57.65 57.37
Resistance 1 (R1) 54.33 54.47 53.29 53.50 56.88
Pivot Point 52.25 52.25 51.74 51.84 52.25
Support 1 (S1) 48.52 50.03 47.48 47.69 44.30
Support 2 (S2) 46.44 48.66 46.03 43.81
Support 3 (S3) 42.71 46.44 43.33
Support 4 (S4) 41.88